Tags

Type your tag names separated by a space and hit enter

Role of BDNF Val66Met functional polymorphism in Alzheimer's disease-related depression.
Neurobiol Aging 2009; 30(9):1406-12NA

Abstract

BACKGROUND

The gene encoding brain-derived neurotrophic factor (BDNF) has been suggested as a candidate for major depression, and for depression susceptibility in different neurological and psychiatric diseases. No study has investigated the role of BDNF genetic variation and depressive symptoms in Alzheimer's disease (AD).

OBJECTIVE

The aim of this study was to assess the genetic contribution of BDNF Val66Met functional polymorphism to AD-related depression.

METHODS

Two-hundred and sixty-four AD patients underwent clinical and neuropsychological examination as well as an evaluation of behavioral and psychiatric disturbances. They were subsequently divided into two subgroups according to the presence (AD-D) or the absence (AD-nD), based on DSM-IV criteria for depression in AD. In each subject, BDNF Val66Met functional polymorphism and apolipoprotein E (APOE) genotype were evaluated.

RESULTS

In our sample, 35.2% of patients (n=93) reported AD-related depressive symptoms. Compared to patients bearing no polymorphisms (BDNF G/G), BDNF G/A carriers showed more than twofold-time risk (OR=2.38; 95%CI=1.38-4.13), and BDNF A/A carriers had a threefold-time risk (OR=3.04; 95%CI=1.15-8.00) for depression in AD. Accordingly, considering the allele frequencies, BDNF A allele was significantly over-represented in AD-D (32.8%) compared to AD-nD (19.0%) (OR=2.08; 95%CI=1.38-3.13). An association between the number of carried A allele and the severity of depressive symptoms was observed (P<0.002). No effect of APOE genotype on risk for depression was found.

CONCLUSIONS

The present findings provide evidence of BDNF genetic variation role in the susceptibility to AD-related depression. This study puts emphasis on the usefulness of considering genetic background for better defining individualized risk profiles in AD.

Authors+Show Affiliations

Center for Aging Brain and Dementia, Department of Neurology, University of Brescia, Italy. bborroni@inwind.itNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

18179845

Citation

Borroni, B, et al. "Role of BDNF Val66Met Functional Polymorphism in Alzheimer's Disease-related Depression." Neurobiology of Aging, vol. 30, no. 9, 2009, pp. 1406-12.
Borroni B, Archetti S, Costanzi C, et al. Role of BDNF Val66Met functional polymorphism in Alzheimer's disease-related depression. Neurobiol Aging. 2009;30(9):1406-12.
Borroni, B., Archetti, S., Costanzi, C., Grassi, M., Ferrari, M., Radeghieri, A., ... Padovani, A. (2009). Role of BDNF Val66Met functional polymorphism in Alzheimer's disease-related depression. Neurobiology of Aging, 30(9), pp. 1406-12. doi:10.1016/j.neurobiolaging.2007.11.023.
Borroni B, et al. Role of BDNF Val66Met Functional Polymorphism in Alzheimer's Disease-related Depression. Neurobiol Aging. 2009;30(9):1406-12. PubMed PMID: 18179845.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Role of BDNF Val66Met functional polymorphism in Alzheimer's disease-related depression. AU - Borroni,B, AU - Archetti,S, AU - Costanzi,C, AU - Grassi,M, AU - Ferrari,M, AU - Radeghieri,A, AU - Caimi,L, AU - Caltagirone,C, AU - Di Luca,M, AU - Padovani,A, AU - ,, Y1 - 2008/01/07/ PY - 2007/07/23/received PY - 2007/10/22/revised PY - 2007/11/24/accepted PY - 2008/1/9/pubmed PY - 2009/10/10/medline PY - 2008/1/9/entrez SP - 1406 EP - 12 JF - Neurobiology of aging JO - Neurobiol. Aging VL - 30 IS - 9 N2 - BACKGROUND: The gene encoding brain-derived neurotrophic factor (BDNF) has been suggested as a candidate for major depression, and for depression susceptibility in different neurological and psychiatric diseases. No study has investigated the role of BDNF genetic variation and depressive symptoms in Alzheimer's disease (AD). OBJECTIVE: The aim of this study was to assess the genetic contribution of BDNF Val66Met functional polymorphism to AD-related depression. METHODS: Two-hundred and sixty-four AD patients underwent clinical and neuropsychological examination as well as an evaluation of behavioral and psychiatric disturbances. They were subsequently divided into two subgroups according to the presence (AD-D) or the absence (AD-nD), based on DSM-IV criteria for depression in AD. In each subject, BDNF Val66Met functional polymorphism and apolipoprotein E (APOE) genotype were evaluated. RESULTS: In our sample, 35.2% of patients (n=93) reported AD-related depressive symptoms. Compared to patients bearing no polymorphisms (BDNF G/G), BDNF G/A carriers showed more than twofold-time risk (OR=2.38; 95%CI=1.38-4.13), and BDNF A/A carriers had a threefold-time risk (OR=3.04; 95%CI=1.15-8.00) for depression in AD. Accordingly, considering the allele frequencies, BDNF A allele was significantly over-represented in AD-D (32.8%) compared to AD-nD (19.0%) (OR=2.08; 95%CI=1.38-3.13). An association between the number of carried A allele and the severity of depressive symptoms was observed (P<0.002). No effect of APOE genotype on risk for depression was found. CONCLUSIONS: The present findings provide evidence of BDNF genetic variation role in the susceptibility to AD-related depression. This study puts emphasis on the usefulness of considering genetic background for better defining individualized risk profiles in AD. SN - 1558-1497 UR - https://www.unboundmedicine.com/medline/citation/18179845/Role_of_BDNF_Val66Met_functional_polymorphism_in_Alzheimer's_disease_related_depression_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0197-4580(07)00458-7 DB - PRIME DP - Unbound Medicine ER -